Governor Hogan Announces Maryland Cancer Moonshot Initiative; $216 Million in Initial Investments in Comprehensive Cancer Centers, Cutting-Edge Research of Treatments and Cures

Published on :

Governor Larry Hogan today announced a new Maryland Cancer Moonshot Initiative to expand and accelerate cancer detection, screening, prevention, treatment, and research in the state. The state is committing $216 million in investments as a down payment to jumpstart this far-reaching initiative to save lives, including the first ever comprehensive cancer center in Prince George’s County.

Baltimore MedTech Sector a Key Asset for Ascending Biotech Cluster, Part One

Published on :

BioBuzz has been reporting on myriad medtech university system spinouts and maturing companies from the Baltimore area for a number of years; we’ve featured a number of exciting and promising individual companies. However, as we’ve stepped back a bit to examine more recent Baltimore biohub developments, it’s become clear that there is an unmistakable groundswell of medtech activity that’s transforming the Baltimore life sciences sector.

Life Science Development Projects Position Baltimore BioMed Ecosystem for Boom

Published on :

The Baltimore biotech ecosystem is thriving. And new, big and bold life sciences development projects are in the works, leading many to project Charm City as the next sector of the BioHealth Capital Region (BHCR) to boom.

Johns Hopkins Scientists Contribute to First Complete Sequence of Human Genome 

Published on :

A group of Johns Hopkins University scientists has collaborated with more than 100 researchers around the world to assemble and analyze the first complete sequence of a human genome, two decades after the Human Genome Project produced the first draft.
The work is part of the Telomere to Telomere (T2T) consortium, led by researchers at the National Human Genome Research Institute (NHGRI); University of California, Santa Cruz; and University of Washington, Seattle.
Johns Hopkins contributed key research to the effort to decipher our DNA—which has remained a mystery despite the initial progress 20 years ago. The revelations are expected to open new lines of molecular and genetic exploration while providing scientists with a clearer picture of how DNA affects the risks of diseases, and how genes are expressed and regulated.

Orgenesis and Johns Hopkins Partner to Boost Cell and Gene Therapy Manufacturing for Point of Care Treatment in Baltimore

Published on :

A new cell and gene therapy point of care treatment facility at Johns Hopkins University, expected to open in 2023, has boosted both the state’s importance, as well as Baltimore’s importance as a lynchpin in the cell and gene therapy industry.

Orgenesis and Johns Hopkins University expand POCare in Maryland through creation of the Maryland Center for Cell Therapy Manufacturing

Orgenesis Logo
Published on :

Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, and The Johns Hopkins University, today announce the next phase of their collaboration. This new phase involves construction of a cell and gene therapy processing facility for point of care treatment of patients at Johns Hopkins which is planned to start in Q2 2022 and is expected to be operational in Q2 of 2023.

Labcorp Strengthens Oncology Leadership Position With the Addition of Personal Genome Diagnostics, a Provider of Comprehensive Liquid Biopsy and Tissue-Based Genomic Products and Services

Published on :

Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has entered into a definitive agreement to acquire Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics with a portfolio of comprehensive liquid biopsy and tissue-based products.

FDA Grants Clearance for Longeviti’s Off-The-Shelf ClearFit® Cover, Accelerating Capability of Ultrasound Imaging after Complex Brain Surgery

Longeviti logo
Published on :

Longeviti Neuro Solutions, developer of the first low-profile intracranial devices that meets the functional and reconstructive needs of brain surgery patients, recently announced that it was granted a 510(k) clearance by the U.S Food and Drug Administration (FDA) for ClearFit® OTS (off-the-shelf).

5 Questions With Bryan Deuber, Biotech Business Development Expert and MPH Student at Johns Hopkins

Photo of Bryan Deuber with his two daughters
Published on :

Since Bryan transitioned from the laboratory to business and corporate development at a global CDMO, he has been interested in improving healthcare for patients in and outside of the clinic by working with internal and external stakeholders involved in the next generation biotherapeutics. Over the years, he has gained insight from various sides of the table through his experience at Johns Hopkins, Morgan Stanley, and, more recently, through the sell-side M&A of Paragon Bioservices to Catalent for $1.2B in May 2019. As director of business development at a stealth biotechnology company, he recently interacted across disciplines, from scientists to CEOs. His experience researching opportunities, gathering intelligence, and organizing teams and data for potential deal execution has allowed him to further develop an extensive network within the BioHealth Capital region to improve healthcare and patient outcomes.